News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Wall St. Treating Pharmaceutical IPOs Like Plague
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
The market for biomedical and pharmaceutical companies going public is sick.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Obesity
Novo buys three early-stage obesity assets from Kallyope as investor pressure mounts
September 21, 2026
·
1 min read
·
Tristan Manalac
IPO
Electra lights up with $350M IPO for pivotal immune-disease drug development
September 18, 2026
·
1 min read
·
Gabrielle Masson
Deals
Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs
September 17, 2026
·
2 min read
·
Michael Gibney
Deals
Fed rate hike won’t hold biotech down despite climbing capital costs
September 17, 2026
·
2 min read
·
Annalee Armstrong
